14 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 19 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 14, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
Follow Primate Diseases: new trials by email Literature Review of Primate Diseases trials Research Report on Primate Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of a Preventative Vaccine for Marburg Virus (mRNA-1519) in Healthy Adult Participants mRNA-1519, Placebo - Marburg Virus Disease (MVD) | Phase 1 | Not yet recruiting | ModernaTX, Inc. | 64 | 2026-11-02 | 2026-11-05 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health rVSV∆G-MARV-GP, Placebo - Marburg Virus Disease | Phase 1 | Active not recruiting | International AIDS Vaccine Initiative | 112 | 2026-03-27 | 2026-10-30 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses. BSY001 for Injection (37.5mg), BSY001 for Injection (75 mg), BSY001 for Injection (150 mg) - Smallpox, Cowpox | Phase 1 | Recruiting | China National Biotec Group Company Limited | 76 | 2025-08-28 | 2026-01-29 |
| A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine MVA strain monkeypox attenuated live vaccine (low dose), MVA strain monkeypox attenuated live vaccine (high dose), Placebo - Monkeypox | Phase 1 | Recruiting | Shanghai Institute Of Biological Products | 120 | 2025-01-22 | 2025-10-03 |
| Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects PHV01, Placebo - Marburg Virus Disease | Phase 1 | Completed | Public Health Vaccines LLC | 36 | 2024-02-05 | 2025-09-05 |
| A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines BNT166a - Monkeypox | Phase 1 / Phase 2 | Completed | BioNTech SE | 96 | 2023-09-21 | 2026-09-15 |
| A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age mRNA-1769, Placebo - Smallpox, Mpox | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 351 | 2023-08-15 | 2025-07-16 |
| Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults cAd3-Marburg, cAd3-EBO-S - Ebola Virus Disease, Marburg Virus Disease | Phase 1 | Completed | Albert B. Sabin Vaccine Institute | 32 | 2021-01-06 | 2022-08-03 |
| Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally, NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day), NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day) - Smallpox, Monkeypox | Phase 1 | Completed | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 90 | 2020-09-04 | 2023-08-04 |
| Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years VAC∆6 vaccine - оnce at a dose of 10⁶ PFU, VAC∆6 vaccine - once at a dose of 10⁷ PFU, VAC∆6 vaccine - twice at a dose of 10⁶ PFU - Smallpox, Monkeypox | Phase 1 | Completed | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 60 | 2019-05-18 | 2023-03-09 |
| A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430 galidesivir, placebo - Marburg Virus Disease | Phase 1 | Completed | BioCryst Pharmaceuticals | 32 | 2018-12-10 | 2021-07-23 |
| cAd3-Marburg Vaccine in Healthy Adults cAd3-Marburg vaccine - Marburg Virus Disease | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 40 | 2018-10-09 | 2022-08-11 |
| A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers Ad26 Zaire Ebola Vaccine, MVA Multi-Filo Ebola Vaccine - Ebola Disease, Marburg Disease | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 65 | 2017-03-24 | 2025-07-29 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers AVI-7288, Placebo - Marburg Hemorrhagic Fever | Phase 1 | Completed | Sarepta Therapeutics, Inc. | 40 | 2013-05-01 | 2014-05-07 |
| Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus AVI-6003, Placebo - Marburg Hemorrhagic Fever | Phase 1 | Completed | Sarepta Therapeutics, Inc. | 30 | 2011-05-01 | 2012-05-07 |
| Evaluating an Ebola and a Marburg Vaccine in Uganda Ebola vaccine, Marburg vaccine, Placebo injection - Ebola Virus Disease, Marburg Virus Disease | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 108 | 2010-02-01 | 2013-01-28 |
| Phase I Trial of an Investigational Small Pox Medication ST-246 Days 1 - 3, ST-246 Days 11 - 13 - Orthopoxviral Disease, Smallpox | Phase 1 | Completed | SIGA Technologies | 12 | 2008-08-01 | 2026-10-01 |
| Ebola and Marburg Virus Vaccines VRC-EBODNA023-00-VP, VRC-MARDNA025-00-VP - Ebola Vaccines, Marburg Virus Disease | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2008-01-25 | 2017-07-02 |
| SIGA-246 to Treat Smallpox Vaccine: SIGA-246 - Vaccinia | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-03-13 | 2017-07-02 |
Marburg Virus Disease (11) · Mpox, Monkeypox (8) · Smallpox (6) · Hemorrhagic Fever, Ebola (4) · Cowpox (3) · Acquired Immunodeficiency Syndrome (1) · Acquired angioedema (1) · Angioedemas, Hereditary (1) · Communicable Diseases (1) · Creutzfeldt-Jakob Syndrome (1) · Disseminated Intravascular Coagulation (1) · Hemorrhagic Fevers, Viral (1) · Hepatitis B (1) · Hepatitis C (1) · Poxviridae Infections (1)
Animal Diseases (19) · Infections (19) · Virus Diseases (19) · Filoviridae Infections (11) · Monkey Diseases (11) · Mononegavirales Infections (11) · RNA Virus Infections (11) · Hemorrhagic Fevers, Viral (10) · DNA Virus Infections (9) · Rodent Diseases (8) · Poxviridae Infections (7) · Angioedema (1) · Blood Coagulation Disorders (1) · Blood-Borne Infections (1)
AVI-7288 (1) · Ebola Vaccines (1) · Injections (1) · NIOCH-14 (1) · Saline Solution (1) · Smallpox Vaccine (1) · galidesivir (1) · tecovirimat (1)
National Institute of Allergy and Infectious Diseases (NIAID) (5) · Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" (2) · ModernaTX, Inc. (2) · Sarepta Therapeutics, Inc. (2) · Albert B. Sabin Vaccine Institute (1) · BioCryst Pharmaceuticals (1) · BioNTech SE (1) · China National Biotec Group Company Limited (1) · International AIDS Vaccine Initiative (1) · Public Health Vaccines LLC (1) · SIGA Technologies (1) · Shanghai Institute Of Biological Products (1)
United States (12) · United Kingdom (3) · China (2) · Russia (2) · Uganda (1)
Vladimir I. Kuzubov, PhD (2) · Alison Heald, MD (1) · Apinya B Vutikullird, MD (1) · Daniel Dickerson, MD, PhD (1) · David Hoover, MD (1) · Hannah Kibuuka, MBChB, MMed, MPH (1) · Joan Fusco, PhD (1) · Melinda Hamer, M.D. (1) · Michael Stevenson, MD (1) · Mohamed Al-Ibrahim, MD (1) · Richard Kenney, MD (1) · Roxana Rustomjee, MBChB (1) · Shuang Li, Master (1)
PMID 1538192, PMID 15577929, PMID 16375711, PMID 25225676, PMID 25426834, PMID 25540891, PMID 26200980, PMID 35182042, PMID 36263798, PMID 36709074, PMID 38366591, PMID 39715748, PMID 42235570, PMID 8237108
272201300017C-18-0-1 (1)